PPT Flow

Pharmacy Industry overview.

Overview about PharmEasy.
Business model – How company generate Revenue.
Recent Acquisitions – brief about major acquisitions.
Key growth drivers for E- Pharma industry.
SWOT analysis.
How the supply chain works in E-Pharma – PharmEasy supply chain.
Traffic and engagement on PharmEasy, 1 Mg website – strategies to increase footfalls on the website.
Marketing Mix – digital sale, online app, promotions etc.
Financial Snapshot – Revenue, margins of PharmEasy, 1 MG.
Revenue breakup – 90% Sale of product, 10% Sale of Services.
Focus on 10% of the business i.e Diagnostics, Lab testing.
Diagnostic industry overview.
Peer comparison for diagnostic businesses.
• Strategies – How they can improve inventory management, How they can leverage
PharmEasy: Financial Snapshot
• Aggressive hiring of
resources to fuel growth
FY21 FY22
leads 5x increase in
8491
Employee cost.
5729
2981 •
2335 Focus should be on
improve margins.
-641 -814
-2731 -2589 • The company has raised
Ope r ati n g Re ve n ue T ot al Expe nse s P rofi l /Los s C ash f rom Ops more than $1.12 billion
across 16 funding rounds
over the years.

PharmEasy Revenue
FY21 FY22
Breakdown
418 81.1
Employee Benefit Expenses 270.30 1459.00 27.7
26
Advertising & Promotion Exp. 135.00 494.00

COGS 2152.00 5113.00 FY22

FY21
EBITDA Margin -22.61% -39.66%

2282 5230
Expense/Rs. Of Op. Revenue Rs. 1.28 Rs. 1.48

ROCE -14.42% -32.11% Sale of Products Sale of Services Other Operating Revenue
Peer Comparison
PharmEasy TATA 1 Mg NetMed

Revenue from Operation (Rs. Crs) 5729 627 108

Employee Expenses (Rs. Crs) 1459 220 23

Advertising Expenses (Rs. Crs) 494 180 2

Total Expenses (Rs. Crs) 8491 1171 101

Profit/Loss (Rs. Crs) -2731 -526 11

EBITDA Margin (%) -39.66% -69.36% 12.39%

Expense/Rs. Of Op. Revenue Rs. 1.48 Rs. 1.87 Rs. 0.94

ROCE (%) -32.11% -94.62% 25.26%

Traffic and Engagement

Total Visits Last 3 Months (In Million)

50 46.5 44.8 46.3

40
30
20
12.3 11.4 11.1
10
0
May-23 Jun-23 Jul-23

PharmEasy 1 Mg

Marketing Channels Distribution

Audience Demographics Comparison
77%
Gender Distribution Age distribution 71%
63% 37% 37%
59%
41% 24% 25%
37% 17% 17%
9% 9% 18% 21%
7% 7% 5% 5%
3% 7% 0% 1%
PharmEasy 1 Mg 18-24 25-34 35-44 45-54 55-64 65+ Direct Organic Paid Search Social
Search
Female Male PharmEasy 1 Mg
PharmEasy 1 Mg
India diagnostics – peer comparison

Diagnostic test offerings across key players Peer – business mix FY22

4,622 4,500
4,100 10%
44% 55%
60%

90%
56% 45%
726 40%
320
DLPL Metropolis SRL Thyrocare
DLPL SRL Metropolis Thyrocare 1 mg

B2B % of FY22 sales B2C % of FY22 sales

How the diagnostic segment of Pharmeasy i.e. Thyrocare

Peer – region mix (% FY22 Sales)
grow in B2C segment????
2 5 3
7
15
6
Franchise model – in order to improve presence in B2C this
28 26 28
14
5
will also helps in increasing the network of Labs and
12
18
improving TAT for test results which will lead to the
25
62 54 29 customer satisfaction / acquisition.
32
21
DLPL
8
Metropolis Thyrocare SRL
Corporate tie up - can provide healthcare packages to
corporates
North West East
South International
Continued…
Price range for top 7 tests - Online peers (1Mg) are significantly lower
than traditional companies and also lower than PharmEasy.
Metropolis DLPL SRL 1 MG PharmEasy
1,800
1,600
1,400 Scope of increasing discount in
1,200
1,000 thyroid profile , Vitamin B12 ???
800
600
400
Corporate tie up - can provide
200 healthcare packages to
0
Vitamin Vitamin Lipid Thyroid Liver Kidney CBC corporates
D 25 B12 Profile Profile Function Function

Average discount on tests (TATA 1 Mg V/S PharmEasy)

-59% -52% -52% -56% -54%

-39%
-54%
-28% -23% -23% -24% -6%
-4%
34%

Vitamin Vitamin Lipid Thyroid Liver Kidney CBC

D 25 B12 Profile Profile Function Function

Average Discount (1 Mg) Average Discount (PharmEasy)

Continued…
FY17 FY18 FY19 FY20 FY21 FY22 9M'23
No. of samples (mn)
DLPL 29 35 42 48 50 66 55
Metropolis 14 16 17 20 19 26 19
SRL 35 38 30 30 24 44 29
Thyrocare 14 16 19 19 16 21 17
Realization per sample (Rs)
DLPL 311 305 288 279 318 316 279

Metropolis 381 404 448 437 525 478 460

SRL 267 259 336 335 439 363 347

Thyrocare 213 218 215 225 313 279 232

• Realisation per sample test is lower for Thyrocare – how they can improve
• Strategy to improve economies of scale in Testing segment – ????? Lower revenue
generation per sample
compare to other
peers – It can affect
the profit
 Increasing clinical labs count – to improve TAT

DLPL Metropolis SRL Thyrocare

FY17 FY22

Collection center’s expanded across players

DLPL Metropolis SRL Thyrocare

FY17 FY22